The stock of Adial Pharmaceuticals Inc (ADIL) has seen a 3.38% increase in the past week, with a -42.82% drop in the past month, and a -54.58% decrease in the past quarter. The volatility ratio for the week is 16.74%, and the volatility levels for the past 30 days are at 20.56% for ADIL. The simple moving average for the last 20 days is -2.17% for ADIL stock, with a simple moving average of -60.07% for the last 200 days.
Is It Worth Investing in Adial Pharmaceuticals Inc (NASDAQ: ADIL) Right Now?
Company’s 36-month beta value is 0.96.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADIL is 14.42M, and currently, short sellers hold a 3.40% ratio of that floaft. The average trading volume of ADIL on July 09, 2025 was 8.25M shares.
ADIL) stock’s latest price update
The stock of Adial Pharmaceuticals Inc (NASDAQ: ADIL) has increased by 2.83% when compared to last closing price of $0.32. Despite this, the company has experienced a 3.38% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-09 that GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of an update to the provisional patent application for AD04 which was filed in July 2024, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).
Analysts’ Opinion of ADIL
Many brokerage firms have already submitted their reports for ADIL stocks, with Rodman & Renshaw repeating the rating for ADIL by listing it as a “Buy.” The predicted price for ADIL in the upcoming period, according to Rodman & Renshaw is $8 based on the research report published on November 14, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ADIL reach a price target of $5. The rating they have provided for ADIL stocks is “Buy” according to the report published on October 30th, 2018.
ADIL Trading at -38.97% from the 50-Day Moving Average
After a stumble in the market that brought ADIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.10% of loss for the given period.
Stock Fundamentals for ADIL
The total capital return value is set at -4.09. Equity return is now at value -217.01, with -176.60 for asset returns.
Currently, EBITDA for the company is -13.2 million with net debt to EBITDA at 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
In a nutshell, Adial Pharmaceuticals Inc (ADIL) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
